All In MedTech

FDA Clearance Tracker · P030052-S012

UROVYSION BLADDER CANCER KIT

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 24, 2014 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 24, 2014

Approved

Time to decision

148 days

Received Aug 29, 2013. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P030052-S012
Device name
UROVYSION BLADDER CANCER KIT
Applicant location
Des Plaines, IL
Received
Aug 29, 2013
Decided
Jan 24, 2014
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P030052

Device type

Device class
Class III

Every decision under product code NSD

FDA's approval statement

As written in FDA's record.

APPROVAL FOR A MANUFACTURING SITE LOCATED AT LEICA BIOSYSTEMS IN SOLON MILLS, ILLINOIS.

Source documents

Other decisions for Abbott Molecular

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.